Antiviral Effects of Human Fibroblast Interferon from Escherichia coli against Encephalomyocarditis Virus Infection of Squirrel Monkeys

References

1. Allen G., Fantes K. H. 1980; A family of structural genes for human lymphoblastoid (leukocyte-type) interferon. Nature, London 287:408–411
   [Google Scholar]
2. Billiau A., Desomer P., Edy V. G., De Clercq E., Heremans H. 1979; Human fibroblast interferon in clinical trials: pharmacokinetics and tolerability in experimental animals and humans. Antimicrobial Agents and Chemotherapy 16:56–63
   [Google Scholar]
3. Billiau A., Heremans H., Ververken D., Van Damme J., Carton H., De Somer P. 1981; Tissue distribution of human interferons after exogenous administration in rabbits, monkeys and mice. Achives of Virology 68:19–25
   [Google Scholar]
4. Bocci V. 1981; Pharmacokinetic studies of interferons. Pharmacologia therapeutica 13:421–440
   [Google Scholar]
5. Campbell J. B., Grunberger T., Kochman M. A., White S. L. 1975; A microplaque reduction assay for human and mouse interferon. Canadian Journal of Microbiology 21:1247–1253
   [Google Scholar]
6. Cesario T., Vaziri N., Slater L., Tilles J. 1979; Inactivators of fibroblast interferon found in human serum. Infection and Immunity 24:851–855
   [Google Scholar]
7. Goeddel D. V., Shepard H. M., Yelverton E., Leung D., Crea R., Sloma A., Pestka S. 1980a; Synthesis of human fibroblast interferon by E. coli. Nucleic Acids Research 8:4057–4074
   [Google Scholar]
8. Goeddel D. V., Yelverton E., Ullrich A., Heyneker H. L., Miozzari G., Holmes W., Seeburg P. H., Dull T., May L., Stebbing N., Crea R., Maeda S., McCandliss R., Sloma A., Tabor J. M., Gross M., Familletti P. C., Pestka S. 1980b; leukocyte interferon produced by E. coli is biologically active. Nature, London 287:411–416
   [Google Scholar]
9. Goeddel D. V., Leung D. W., Dull T. J., Gross M., Lawn R. M., McCandliss R., Seeburg P. H., Ullrich A., Yelverton E., Gray P. W. 1981; The structure of eight distinct cloned leukocyte interferon cDNAs. Nature, London 290:20–26
   [Google Scholar]
10. Hanley D. F., Wiranowska-Stewart M., Stewart W. E. 1979; Pharmacology of interferons. I. Pharmacologic distinctions between human leukocyte and fibroblast interferons. International Journal of Immunopharmacology 1:219–226
    [Google Scholar]
11. Harkins R. N., Hass P. E., Kohr W. H., Aggarwal B. B., Weck P. K., Apperson S. 1982; Structural and biological properties of purified bacteria-derived human fibroblast interferon. Proceedings of the National Academy of Sciences of the United states of America (in press)
    [Google Scholar]
12. Peto R., Pike M. C. 1973; Conservatism of the approximation in the logrank test for survival data or tumor incidence data. Biometrics 29:579–584
    [Google Scholar]
13. Schellekens H., Dereus A., Bolhuis R., Fountoulakis M., Schein C., Ecsodi J., Nagata S., Weissmann C. 1981; Comparative antiviral efficiency of leukocyte and bacterially produced human α-interferon in rhesus monkeys. Nature, London 292:775–776
    [Google Scholar]
14. Strueli M., Nagata S., Weissmann C. 1980; At least three human type alpha interferons. Structure of alpha two. Science 209:1343–1347
    [Google Scholar]
15. Taniguchi T., Ohno S., Fuji-Kuriyama Y., Muramatsu M. 1980; The nucleotide sequence of human fibroblast interferon cDNA. Gene 10:11–15
    [Google Scholar]
16. Vilcek I., Sulea I. T., Zerebeckyj I. L., Yip Y. K. 1980; Pharmacokinetic properties of human fibroblast and leukocyte interferon in rabbits. Journal of Clinical Microbiology 11:102–106
    [Google Scholar]
17. Weck P. K., Apperson S., May L., Stebbing N. 1981; Comparison of the antiviral activities of various cloned human interferon-alpha subtypes in mammalian cell cultures. Journal of General Virology 57:233–237
    [Google Scholar]